Abstract: The present disclosure relates to a nanoparticle complex that is taken into cells to be used for the treatment of diseases, and a method of manufacturing the same using a top-down process. In the top-down process, surfaces of nanoparticles are modified with a lipid-based material having high stability and excellent biocompatibility, thereby improving endocytosis efficiency. A lipid structure having a tube shape is bonded to a portion of the surface of the nanoparticle, so that the nanoparticle complex undergoes endocytosis, directly penetrates a cell membrane, and is effectively taken into spheroid-type tumor cells. The lipid structure is not directly attached to the nanoparticles, lipid-based lipidomes (such as bubbles and liposomes) are bonded to the nanoparticles, and mechanical force is applied thereto to thus crush the lipidomes, so that the lipid structure is formed on the surface of the nanoparticle.

Abstract: A method of synthesizing silymarin-loaded collagen collagen nanoparticles can include dissolving silymarin in an alcohol to provide a solution, mixing the solution with acetic acid to provide an acetic acid mixture, and adding the glutaraldehyde to the mixture to provide silymarin nanoparticles. The silymarin nanoparticles can be dissolved in a further alcohol and mixed for a period of time to provide a silymarin nanoparticle mixture. Then, the silymarin nanoparticles can be mixed with collagen nanoparticles to provide a silymarin/collagen mixture. Glutaraldehyde can be added to the collagen mixture to provide the nanocomposite formulation.

Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Abstract: Disclosed is a dissolvable solid article, comprising by weight of the article: from about 10% to about 50% of a water soluble polymer; from about 20% to about 80% of a surfactant; from about 0.5% to about 2% of diaminocarboxylic acid chelants and salts thereof having an average molecular weight in acid form of from about 250 to about 450 daltons and having a weighted log P value at pH 4 of from about ?12 to about ?7; from about 0.1% to about 6% of an aromatic carboxylic acid and salts thereof having an average molecular weight in acid form of from about 100 to about 400 daltons and having a weighted log P value at pH 4 of from about ?2 to about 4; from about 0.1% to about 18% of an non-aromatic organic alpha hydroxy acid and salts thereof; wherein the dissolvable solid article has a pH of from about 3 to about 5.1 when dissolved with 30 parts water to 1 part of the dissolvable solid article.

Abstract: A mouth rinse composition with a cationic antimicrobial agent and an anti-stain agent, which is a functionalized polyethylene glycol. A dentifrice composition with a cationic antimicrobial agent and an anti-stain agent, which is a functionalized polyethylene glycol. The cationic antimicrobial agent is a quaternary ammonium salt, such as cetyl pyridinium chloride, or a metal ion source, such as stannous fluoride.

Abstract: The present invention relates to a method for applying false eyelashes, comprising: a step of applying, on the root of the eyelashes of the eyelid of a person, a magnetic composition comprising fine magnetic particles; and a step of applying, on the composition deposited in the previous step, a magnetic false eyelash.

Abstract: This application provides, among other things, novel aqueous oral care compositions useful for combining and delivering poorly compatible ingredients, in particular, chlorhexidine and polyphosphate salts, by formulating the composition with a surfactant.

Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

Abstract: In some embodiments provided herein is a method of treating hip pain in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Abstract: The disclosure generally relates to lipid nanodiscs, in particular to lipid nanodiscs formed from polymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and a polymer encircling the hydrophobic edge of the lipid bilayer. The polymer includes a first monomeric unit having a pendant hydrophobic group and a second monomeric unit having a backbone hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

Abstract: This disclosure provides treatment kit that are capable of modulating the immune response. The treatment kit may also be used enhance the immunogenicity of antigens released from cell debris. Also provided are methods of using the treatment kit.

Abstract: In some embodiments provided herein is a method of treating hip pain in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

Abstract: A drug delivery system having an inner core-shell like structure containing a poorly soluble camptothecin compound and a water-soluble camptothecin compound, and an outer amphiphilic polymer shell surrounding the inner core-shell like structure, a manufacturing method therefor, and uses of the drug delivery system in treating cancer are disclosed. The core-shell structured particles form very stable particles and show a mono-distribution of particles before and after freeze-drying. The particles show excellent results compared with existing particles which do not contain the inner core-shell like structure, in animal efficacy tests and pharmacokinetic tests.

Abstract: A drug delivery system having an inner core-shell like structure containing a poorly soluble camptothecin compound and a water-soluble camptothecin compound, and an outer amphiphilic polymer shell surrounding the inner core-shell like structure, a manufacturing method therefor, and uses of the drug delivery system in treating cancer are disclosed. The core-shell structured particles form very stable particles and show a mono-distribution of particles before and after freeze-drying. The particles show excellent results compared with existing particles which do not contain the inner core-shell like structure, in animal efficacy tests and pharmacokinetic tests.

Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.

Abstract: The purpose of the present invention is to provide a water-in-oil type emulsion cosmetic that has a replenishing and smooth feel-of-use, that, once applied, forms a uniform coating, and that can minimize the appearance of skin roughness such as pores while covering discoloration such as spots and freckles, but that does not give an impression of a thick coating. The present invention provides a water-in-oil type emulsion cosmetic characterized by containing (A) 0.1-20 mass % of metallic soap-treated powder, and (B) a water-absorptive polymer having 0.01-2 mass % of a carboxyl group. The (B) water-absorptive polymer having a carboxyl group of this cosmetic preferably can absorb 10-1,000 times its own weight.

Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

Abstract: Described herein is a hybrid biological membrane comprising an endogenous bilayer doped with one or more synthetic lipid molecules. Also described herein is a method of preparing a hybrid biological membrane, the method comprising doping an endogenous bilayer with one or more synthetic lipid molecules.

Abstract: The present invention relates to effect pigments which are based on flake-form substrates having a circular form factor of 1.2-2 and are coated with at least one high-refractive-index layer, and to the use thereof, inter alia in paints, coatings, printing inks, plastics and in cosmetic formulations.